The human liver is susceptible to interference due to its complex function. The development ofhepatoprotective from jamu formula is still needed as to produce more effective, cheaper andsafer hepatoprotective. The result of previous study showed that the hepatoprotective from jamuformula was safe and efficacious. This phase 2 trial was conducted to evaluate the efficacy andsafety of hepatoprotective from jamu formula which consists of Curcuma longa rhizomes, Curcumaxanthorrhiza rhizomes, and Taraxacum officinale leaves. The design was open label randomizedclinical trial with silimarin as a comparison for 42 days intervention. Two hundreds of humansubjects participated in this study. The trial held in 2015 and involved 50 physician members ofSaintifikasi Jamu Network at several regencies in Indonesia. The parameters for assessing efficacywere SGPT, SGOT and as for safety were routine blood, urea, and creatinine. Clinical symptoms andpossible side effects were also observed. The results showed that the jamu formula can reduce theaverage value of SGPT and SGOT equal to silimarin. Jamu formula can relieve clinical symptomsarising from liver function disruption, and it is safe, it does not alter kidney function, hemoglobin,leukocyte count and platelet count in its use for 42 days.